Progress your anti-inflammatory agents with our preclinical drug development platform of thoroughly validated peritonitis models.
Key Benefits
Effectively determine preclinical drug efficacy and model response to treatment.
Perform mechanistic assessment of anti-inflammatory compounds via rapid and simple assessment of leukocyte recruitment and acute inflammatory response.
Partner with our experienced team for expert consultation and custom model builds
Choose from a range of models recapitulating various types of acute inflammation:
Monosodium urate (MSU) induced peritonitis model
Zymosan-induced peritonitis model
fMLP, LPS/sepsis, and thioglycollate-induced models coming soon.
Monosodium Urate-Induced “Gout” Peritonitis Model
Perform simple and rapid evaluation of agent inflammasome-mediated acute inflammatory response.
Effectively characterize inflammatory exudates including PMNs and IL-1β, with ample volumes collected from peritoneal cavities compared to smaller joint synovial fluid volumes.
Peritonitis induced via 3mg MSU crystal injection i.p., with fluid lavaged from peritoneal cavities 4-6 hours later.
Zymosan-Induced Peritonitis Model
Rapidly assess an agent’s ability to attenuate acute TLR-activated inflammation associated with peritonitis.
Accurately investigate your compounds’ effect on various immune components including neutrophils, eosinophils, and macrophages.
Peritonitis induced by i.p. injection of 0.5mg zymosan, a yeast cell wall component and TLR2 agonist, with fluid lavaged from peritoneal cavities 6-48 hours later dependent upon immune cell populations of interest.
Evaluate Major Study Endpoints
Flow cytometry analysis for leukocytes of interest such as PMNs and macrophages.
Cytokine levels measured by ELISA or MSD.
Inflammatory gene expression of recruited leukocytes measured by qPCR.
